Whitehawk Therapeutics, Inc.·4

Apr 10, 6:46 PM ET

Lennon David James 4

4 · Whitehawk Therapeutics, Inc. · Filed Apr 10, 2026

Research Summary

AI-generated summary of this filing

Updated

Whitehawk (WHWK) CEO Lennon David James Sells 14,500 Shares

What Happened
Lennon David James, Chief Executive Officer of Whitehawk Therapeutics, sold 14,500 shares on April 9, 2026. The shares were sold at $3.38 each for total proceeds of $49,010. This was a sale (not a purchase) and appears to be a routine, non-investment sale tied to equity compensation.

Key Details

  • Transaction date: 2026-04-09
  • Price per share: $3.38; total proceeds: $49,010
  • Transaction type/code: Sale (S) — broker-assisted sale
  • Footnote: Broker-assisted sale to satisfy the reporting person’s tax withholding obligations in connection with the vesting of restricted stock units (RSUs) (Footnote F1).
  • Shares owned after transaction: Not disclosed in this filing.
  • Filing: Form 4 filed 2026-04-10 (appears timely; no late filing indicated).

Context
Broker-assisted sales to cover tax withholding for vested RSUs are common and generally considered routine compensation-related transactions rather than a direct signal about the insider’s view of the company’s stock.

Insider Transaction Report

Form 4
Period: 2026-04-09
Lennon David James
DirectorCHIEF EXECUTIVE OFFICER
Transactions
  • Sale

    Common Stock

    [F1]
    2026-04-09$3.38/sh14,500$49,010518,622 total
Footnotes (1)
  • [F1]Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
Signature
/s/ Stephen Rodin, as Attorney-in-Fact|2026-04-10

Documents

1 file
  • 4
    form4-04102026_100459.xmlPrimary